β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells

Sajni Josson, Takeo Nomura, Jen Tai Lin, Wen Chin Huang, Daqing Wu, Haiyen E. Zhau, Majd Zayzafoon, M. Neale Weizmann, Murali Gururajan, Leland W.K. Chung

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Bone metastasis is one of the predominant causes of cancer lethality. This study demonstrates for the first time how β2-microglobulin (β2-M) supports lethal metastasis in vivo in human prostate, breast, lung, and renal cancer cells. β2-M mediates this process by activating epithelial to mesenchymal transition (EMT) to promote lethal bone and soft tissue metastases in host mice. β2-M interacts with its receptor, hemochromatosis (HFE) protein, to modulate iron responsive pathways in cancer cells. Inhibition of either β2-M or HFE results in reversion of EMT. These results demonstrate the role of β2-M in cancer metastasis and lethality. Thus, β2-M and its downstream signaling pathways are promising prognostic markers of cancer metastases and novel therapeutic targets for cancer therapy.

Original languageEnglish (US)
Pages (from-to)2600-2610
Number of pages11
JournalCancer Research
Volume71
Issue number7
DOIs
StatePublished - Apr 1 2011

Fingerprint

Bone Neoplasms
Epithelial-Mesenchymal Transition
Neoplasm Metastasis
Neoplasms
Bone and Bones
Kidney Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Iron
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. / Josson, Sajni; Nomura, Takeo; Lin, Jen Tai; Huang, Wen Chin; Wu, Daqing; Zhau, Haiyen E.; Zayzafoon, Majd; Neale Weizmann, M.; Gururajan, Murali; Chung, Leland W.K.

In: Cancer Research, Vol. 71, No. 7, 01.04.2011, p. 2600-2610.

Research output: Contribution to journalArticle

Josson, S, Nomura, T, Lin, JT, Huang, WC, Wu, D, Zhau, HE, Zayzafoon, M, Neale Weizmann, M, Gururajan, M & Chung, LWK 2011, 'β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells', Cancer Research, vol. 71, no. 7, pp. 2600-2610. https://doi.org/10.1158/0008-5472.CAN-10-3382
Josson, Sajni ; Nomura, Takeo ; Lin, Jen Tai ; Huang, Wen Chin ; Wu, Daqing ; Zhau, Haiyen E. ; Zayzafoon, Majd ; Neale Weizmann, M. ; Gururajan, Murali ; Chung, Leland W.K. / β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. In: Cancer Research. 2011 ; Vol. 71, No. 7. pp. 2600-2610.
@article{1c35f6bab4e54c049db7e2a538b514eb,
title = "β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells",
abstract = "Bone metastasis is one of the predominant causes of cancer lethality. This study demonstrates for the first time how β2-microglobulin (β2-M) supports lethal metastasis in vivo in human prostate, breast, lung, and renal cancer cells. β2-M mediates this process by activating epithelial to mesenchymal transition (EMT) to promote lethal bone and soft tissue metastases in host mice. β2-M interacts with its receptor, hemochromatosis (HFE) protein, to modulate iron responsive pathways in cancer cells. Inhibition of either β2-M or HFE results in reversion of EMT. These results demonstrate the role of β2-M in cancer metastasis and lethality. Thus, β2-M and its downstream signaling pathways are promising prognostic markers of cancer metastases and novel therapeutic targets for cancer therapy.",
author = "Sajni Josson and Takeo Nomura and Lin, {Jen Tai} and Huang, {Wen Chin} and Daqing Wu and Zhau, {Haiyen E.} and Majd Zayzafoon and {Neale Weizmann}, M. and Murali Gururajan and Chung, {Leland W.K.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-10-3382",
language = "English (US)",
volume = "71",
pages = "2600--2610",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells

AU - Josson, Sajni

AU - Nomura, Takeo

AU - Lin, Jen Tai

AU - Huang, Wen Chin

AU - Wu, Daqing

AU - Zhau, Haiyen E.

AU - Zayzafoon, Majd

AU - Neale Weizmann, M.

AU - Gururajan, Murali

AU - Chung, Leland W.K.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Bone metastasis is one of the predominant causes of cancer lethality. This study demonstrates for the first time how β2-microglobulin (β2-M) supports lethal metastasis in vivo in human prostate, breast, lung, and renal cancer cells. β2-M mediates this process by activating epithelial to mesenchymal transition (EMT) to promote lethal bone and soft tissue metastases in host mice. β2-M interacts with its receptor, hemochromatosis (HFE) protein, to modulate iron responsive pathways in cancer cells. Inhibition of either β2-M or HFE results in reversion of EMT. These results demonstrate the role of β2-M in cancer metastasis and lethality. Thus, β2-M and its downstream signaling pathways are promising prognostic markers of cancer metastases and novel therapeutic targets for cancer therapy.

AB - Bone metastasis is one of the predominant causes of cancer lethality. This study demonstrates for the first time how β2-microglobulin (β2-M) supports lethal metastasis in vivo in human prostate, breast, lung, and renal cancer cells. β2-M mediates this process by activating epithelial to mesenchymal transition (EMT) to promote lethal bone and soft tissue metastases in host mice. β2-M interacts with its receptor, hemochromatosis (HFE) protein, to modulate iron responsive pathways in cancer cells. Inhibition of either β2-M or HFE results in reversion of EMT. These results demonstrate the role of β2-M in cancer metastasis and lethality. Thus, β2-M and its downstream signaling pathways are promising prognostic markers of cancer metastases and novel therapeutic targets for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=79953299688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953299688&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-3382

DO - 10.1158/0008-5472.CAN-10-3382

M3 - Article

C2 - 21427356

AN - SCOPUS:79953299688

VL - 71

SP - 2600

EP - 2610

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -